COMPANY

Inhibrx Biosciences

HQ: La Jolla, CA source · inhibrx.com ↗ · West Coast

Location: La Jolla, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Non-Small Cell Lung Cancer Melanoma Renal Cell Carcinoma Ewing Sarcoma Colorectal Adenocarcinoma Head and Neck Cancer Gastric Cancer Urothelial Carcinoma Resectable Non-Small-Cell Lung Cancer Conventional Chondrosarcoma Head and Neck Squamous Cell Carcinoma Gastric Adenocarcinoma Esophageal Adenocarcinoma Nasopharyngeal Carcinoma Oropharyngeal Carcinoma Alpha-1 Antitrypsin Deficiency AATD INBRX-109 INBRX-106

6Trials (company is sponsor)

Timeline

Jul 16, 2026 Debt Debt: $500M (not counted as a raise), announced Jul 16, 2026. Source: SEC filing. source ↗
Jan 13, 2025 Debt Debt financing: $150M (up to, as announced), announced Jan 13, 2025. Source: SEC filing. source ↗
May 14, 2024 Trial start Phase 2/Phase 3: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC source ↗
Sep 23, 2021 Trial start Phase 2: Study of INBRX-109 in Conventional Chondrosarcoma source ↗
Dec 10, 2019 Trial start Phase 1/Phase 2: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) source ↗
Jul 19, 2019 Trial start 1: Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency source ↗
Jan 30, 2019 Trial start Phase 1: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer source ↗
Oct 8, 2018 Trial start 1: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas source ↗

Upcoming milestones

2028-12 (ESTIMATED) · 1 · Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas · NCT03715933
2029-05 (ESTIMATED) · Phase 2/Phase 3 · INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC · NCT06295731
2033-07 (ESTIMATED) · Phase 1/Phase 2 · Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) · NCT04198766

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Debt: $650.0M. Last 2 years.

Jul 16, 2026 Debt: $500M (not counted as a raise), announced Jul 16, 2026. Source: SEC filing. source ↗
Jan 13, 2025 Debt financing: $150M (up to, as announced), announced Jan 13, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT03715933	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	1	Recruiting	Oct 8, 2018	2028-12 (estimated)
NCT04198766	Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)	Phase 1/Phase 2	Recruiting	Dec 10, 2019	2033-07 (estimated)
NCT04950075	Study of INBRX-109 in Conventional Chondrosarcoma	Phase 2	Active, not recruiting	Sep 23, 2021	Sep 30, 2025 (actual)
NCT06295731	INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC	Phase 2/Phase 3	Active, not recruiting	May 14, 2024	2029-05 (estimated)
NCT03809624	Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer	Phase 1	Terminated	Jan 30, 2019	Oct 3, 2024 (actual)
NCT03815396	Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency	1	Completed	Jul 19, 2019	Aug 18, 2022 (actual)